Susquehanna International Group, LLP Inmune Bio, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.86 - $9.86 $708,588 - $1.44 Million	145,800 Added 215.68%	213,400 $1.15 Million
Q2 2024 Aug 15, 2024	BUY	$7.15 - $11.84 $317,460 - $525,696	44,400 Added 191.38%	67,600 $596,000
Q1 2024 May 07, 2024	SELL	$10.53 - $14.01 $131,625 - $175,125	-12,500 Reduced 35.01%	23,200 $272,000
Q4 2023 Feb 14, 2024	BUY	$6.6 - $11.52 $137,280 - $239,616	20,800 Added 139.6%	35,700 $401,000
Q3 2023 Nov 14, 2023	SELL	$6.61 - $10.9 $5,949 - $9,810	-900 Reduced 5.7%	14,900 $100,000
Q2 2023 Aug 11, 2023	BUY	$6.5 - $10.09 $102,700 - $159,422	15,800 New	15,800 $143,000
Q4 2022 Feb 14, 2023	SELL	$6.13 - $7.96 $70,495 - $91,540	-11,500 Reduced 53.24%	10,100 $64,000
Q3 2022 Nov 14, 2022	SELL	$6.04 - $10.44 $29,596 - $51,156	-4,900 Reduced 18.49%	21,600 $134,000
Q2 2022 Aug 15, 2022	SELL	$5.48 - $8.97 $81,652 - $133,653	-14,900 Reduced 35.99%	26,500 $234,000
Q3 2021 Nov 15, 2021	BUY	$14.13 - $27.85 $584,982 - $1.15 Million	41,400 New	41,400 $804,000

5.88M

243K

46.4K

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $89M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.